Blood Advances (Nov 2019)
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
- Drew Provan,
- Donald M. Arnold,
- James B. Bussel,
- Beng H. Chong,
- Nichola Cooper,
- Terry Gernsheimer,
- Waleed Ghanima,
- Bertrand Godeau,
- Tomás José González-López,
- John Grainger,
- Ming Hou,
- Caroline Kruse,
- Vickie McDonald,
- Marc Michel,
- Adrian C. Newland,
- Sue Pavord,
- Francesco Rodeghiero,
- Marie Scully,
- Yoshiaki Tomiyama,
- Raymond S. Wong,
- Francesco Zaja,
- David J. Kuter
Affiliations
- Drew Provan
- Academic Haematology Unit, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom;; Drew Provan, Department of Haematology, The Royal London Hospital, Pathology and Pharmacy Building, London E1 2ES, United Kingdom;
- Donald M. Arnold
- McMaster Centre for Transfusion Research, Department of Medicine and Department of Pathology and Molecular Medicine, McMaster University and Canadian Blood Services, Hamilton, ON, Canada;
- James B. Bussel
- Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY;
- Beng H. Chong
- St. George Hospital, NSW Health Pathology, University of New South Wales, Sydney, NSW, Australia;
- Nichola Cooper
- Department of Haematology, Hammersmith Hospital, London, United Kingdom;
- Terry Gernsheimer
- Seattle Cancer Care Alliance, University of Washington, Seattle, WA;
- Waleed Ghanima
- Departments of Research, Medicine and Oncology, Østfold Hospital Trust, Grålum, Norway;; Department of Hematology, Institute of Clinical Medicine, Oslo University, Oslo, Norway;
- Bertrand Godeau
- Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Service de Médecine Interne, CHU Henri Mondor, AP-HP, Université Paris-Est Créteil, Créteil, France;
- Tomás José González-López
- Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain;
- John Grainger
- Department of Haematology, Royal Manchester Children's Hospital, Manchester, United Kingdom;
- Ming Hou
- Department of Haematology, Qilu Hospital, Shandong University, Jinan, China;
- Caroline Kruse
- Platelet Disorder Support Association, Cleveland, OH;
- Vickie McDonald
- Royal London Hospital, Barts Health NHS Trust, London, United Kingdom;
- Marc Michel
- Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Service de Médecine Interne, CHU Henri Mondor, AP-HP, Université Paris-Est Créteil, Créteil, France;
- Adrian C. Newland
- Academic Haematology Unit, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom;
- Sue Pavord
- Haematology Theme Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;
- Francesco Rodeghiero
- Hematology Project Foundation, Affiliated to the Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy;
- Marie Scully
- Department of Haematology, University College London Hospital, Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, United Kingdom;
- Yoshiaki Tomiyama
- Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan;
- Raymond S. Wong
- Sir YK Pao Centre for Cancer and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong;
- Francesco Zaja
- SC Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste, Italy
- David J. Kuter
- Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- Journal volume & issue
-
Vol. 3,
no. 22
pp. 3780 – 3817
Abstract
Abstract: Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify all relevant articles published between 2009 and 2018. An expert panel screened, reviewed, and graded the studies and formulated the updated consensus recommendations based on the new data. The final document provides consensus recommendations on the diagnosis and management of ITP in adults, during pregnancy, and in children, as well as quality-of-life considerations.
